MLC Runners

We Hate To Run

Oncotarget is a medical journal that is multi disciplinary and its main focus being oncology. Oncortarget is notable for being highly active by publishing twice every week. This makes it the first journal in the medical field to complete the submission of an issue to medical databases in a few weeks.

This makes it one of the most reliable medical research journal online and can be used by the growing number of online users worldwide in the medical research concerning matters of oncology and other medical fields such as pathology , microbiology, chromosomes and autophagy. Check the journal at SCImago Journal & Country Rank.

The journal has released 324 issues since 2010 achieving a publication of seven volumes and currently working on the 8th volume. The journal is known for giving every paper it publishes a direct object identifier also known as the (DOI). Besides giving every paper a DOI it also considers the recommendations of the committee of Publication Ethics abbreviated as (COPE)in its publications.

The journal works with the most prominent scientists so as to be able to conquer diseases throuh research and growth of the medical field. Its main aim is to get rid of diseases and make the world a better place for human inhabitation. It has gone a long way in creating a scientific olatform where Gurus in the field can share their ideas in the medical field and together create a better place for human inhabitation. Clearly, some humans are spending sleepless nights so as to make the world a better place. Follow Oncotarget journal on Twitter.

Oncotarget- The Multi-disciplinary Medical Journal

Oncotarget is a multi-disciplinary journal that has a free access. The Journal is also peer-reviewed and releases two issues every week. Oncotarget publishes papers online that are aimed at making resources available in the field of medical research through and insightful research and getting rid of boundaries that have been put forward in medical research. It encourages the application of both clinical and basic science the the war against disease. It is also led by the most prominent medical scientists and leads the fight against human ailments and diseases. It main goal is to see a world without disease.

Follow: https://www.linkedin.com/company/oncotarget

Background

According to cancer.gov, a website dedicated to all things cancer-related, statistics show that in the year 2016, it was approximated that around 1,685,210 new cases of cancer will be diagnosed in the United States and 595,690 people will die from the horrible disease. Those same statistics further show how the number of cancer deaths is 171.2 per 100,000 men and women per year. Dealing with numbers such as those is why men like Mikhail Blagosklonny are seen as miracle workers.Having a career that spans decades, Mikhail Blagosklonny has dedicated his career to studing Aging and Cancer as a scientist, most notably working professor of Oncology at the Roswell Park Cancer Institute. Having earned both his M.D. in internal medicine and his Ph.D. in experimental medicine and cardiology from the reputable First Pavlov State Medical University of St. Peterburg, Mikhail Blagosklonny has gone on to do incredible research and has provided extraordinary results for many distinguished facilities in his field that are sure to make his alma mater proud. To further understand the great work of Mikhail Blagosklonny, let’s take a look articles about Mikhail’s research with Rapamycin as well as an about Mikhail’s plans for oncology which speak about their titles respectively.

Mikhail Blagosklonny’s research with Rapamycin

In this article by the vyper.tv website title “Mikhail Blagosklonny and His Unwavering Belief in Rapamycin”, it goes on to explain how the notable breakthrough discovery of Rapamycin and its healing properties have not gone unnoticed, especially since it has potential in the fight against cancer. The article further explains the healing powers of Rapamycin and its abilities such as being able to prevent tissue rejection after a successful organ transplant. Needless to say, Mikhail Blagosklonny has been greatly appreciated and respected for his contributions to this discovery. In fact, the article also explains how studies have shown a lot of promise and will save lives, which makes him a miracle worker. There have been many doctors that have dedicated their lives towards the fight against cancer, however, very little can say they have achieved the amount of prosperity that Mikhail Blagosklonny has with this discovery.

Mikhail Blagosklonny’s plans for oncology

In a second article by the website healingmagic.net appropriately titled “Mikhail Blagosklonny’s Plans for Oncology“, it goes on to explain how Mikhail Blagosklonny is a person who wants to make the world a better place in the fight against cancer. Specifically, he is helping in that effort by making sure that individuals from any social background and status have only the best treatment possible. The article also explains how in the great strides that Mikhail Blagosklonny has made in his research of both cancer and aging, he makes it a priority to meet the needs of all who are affected by the diseases he is working on eradicating. In addition to showing his generosity in his efforts, the article also goes on to explain how he is also thinking towards the future. In other words, it means that Mikhail Blagosklonny has also made it a priority for his progress within his field will inspire other individuals around the world to pick up where he will leave off for future studies. If that doesn’t show how uniquely special Mikhail Blagosklonny is, not much else will.

Oncotarget is a subsidiary of impact journal that covers several oncology disciplines. The journal is weekly released, peer-reviewed, open source, and covers all aspects of oncology. Impact Journals first established Oncotarget in 2010. Andrei V. Gudkov and Mikhail Blagosklonny serve at Oncotarget, Roswell Park Cancer Institute, as editors in chief. IntegraGen is another profounder company that transforms biological samples data to diagnostic tools and genomic information for oncology. IntegraGen announced that Oncotarget has published results of tumor miR-31-3p expression trials on tumor samples taken from NEW EPOC clinical patients. The paper demonstrates a clear relationship between efficacies of anti-EGFR treatment and miR-31-3p expression. The publication further indicates that patient miR-31-3p expression levels are helpful in determining the efficacy of anti-EGFR therapy in treating RAS wild-type metastatic colorectal cancer. Prof. John, the coauthor of the publication, serves as the investigator at New EPOC Study. He was particularly thrilled that they were able to offer more insights on metastatic colorectal cancer treatment.

Oncotarget peer-reviewed publications are also helpful in assessing patient miR-31-3p in tumors. Yann Gaston-Mathe, IntegraGen Director of Molecular Diagnostics, stated that the practice has introduced a new level of medical precision. He also expressed his confidence in generating adoption and miR-31-3p coverage expression testing. IntegraGen has also announced European commercial launch and CE-IVD Marking of miRpredX 31-3p kit. The kit is user-friendly and helps in quantifying formalin fixed miR-31-3p expression.The agreement made with CERBRA Laboratories to carry out medical tests will equally ease miR-31-3pmeasurement. IntegraGen is a pioneering firm that deciphers human genome to derive vital data for both private and academic laboratories. IntegraGen’s treatment approach is resourceful to various researchers and other clinicians. The firm offers personalized treatments using modern tools and equipment. This approach has holistically enabled them to tackle a range of patient genetic profiles.

IntegraGen works with over 38 professionals and has accumulated a revenue of €6.0 million. The firm serves its locals at Evry Genopole. The IntegraGen also serve several clients in the United States of America. Metastatic Colorectal Cancer is a common type of cancer, this type of cancer affects over 345,000 Europeans and more than 135,000 Americans annually. Most patients who have metastatic colorectal cancer are more likely to have RAS wild-type tumors.Oncotarget vitality is widely spread and has led the company to increase on its publishing scale. The company publishes a minimum of two issues every week. The primary goal is to share all scientific information widely. This new rate of publishing journals is ultimately expected to positively impact on the future by widening the scope of science.Oncotarget runs as an online free source traditional journal. Their papers are in high demand and resourceful to several people and firms that practice oncology. The specialty of the company in its niche of operation has competently improved on the availability of scientific knowledge. Exceptional research discoveries and findings can now be shared promptly through the company’s official online portal. Finally, most journals at Oncotarget focus on cancer pathology, therapy, and all relevant treatment protocols reserved to manage patients and improve their quality of life.

Modern cancer treatments have allowed patients with the most serious forms of the disease to live for periods of time that, in centuries past, were scarcely imaginable. Since the 1950s, diseases like prostate cancer and even lung cancer have become not just fightable but beatable. Initially, these incredible gains in the fight against cancer were attributable primarily to the three main types of cancer treatment that took hold since the 1940s. These were radiation, chemotherapy and surgery. Unfortunately, all of these treatments had horrible side effects, including permanent disability and even death from the treatment itself.

It was the horrible side effects themselves that led to the search for new and more tolerable forms of cancer treatment that would retain or even improve upon the effectiveness of the old treatments. Throughout the late 1980s and 1990s, a new kind of cancer treatment began to take hold. This was known as targeted cancer therapy, a class of drugs that targets the cancer cells individually, leading to the reduction or elimination of many of the terrible side effects associated with such treatment as chemotherapy and radiation.

One of the key figures in the development of targeted cancer therapy has been Clay Siegall. As a researcher for the National Cancer Institute for more than four years and for Bristol-Myers Squibb for almost an entire decade, Dr. Siegall has worked on some of the most cutting-edge targeted cancer treatments in the world today. He was one of the first to begin synthesizing a viable treatment in the form of antibody drug conjugates, a technology that uses human antibodies or synthetic antibodies to deliver a highly lethal cytotoxin directly to the surface of the tumor. This ability to only release the cytotoxin on contact with a malignant tissue virtually eliminates the systemic release of the chemotherapeutic agent into the bloodstream. In theory, this has the capability of completely eliminating all side effects from the treatment.

In 1998, Dr. Siegall went on to found his own company, Seattle Genetics, which was solely dedicated to the development of new forms of antibody drug conjugates. Throughout the 2000’s, Dr. Siegall began zeroing in on a particular form of antibody drug conjugate that would treat a form of cancer, non-Hodgkin’s lymphoma, that had not seen significant improvement over the prior decades.

The resultant drug was ADCetris. Today, ADCetris saves thousands of lives every year.